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transplanted in ﬁrst CR otherwise all patients were
transplanted in relapsed/refractory setting. Patients were
grouped according to conditioning regimens.We aimed to
analyze the difference between the groups due to the total
number of febrile neutropenic days and hospitalization .We
also planned to compare the engraftment kinetics and side
effects between the groups.Table 1.
Patient demographics
BEAM(n:42) ICE(n:26)
Diagnosis
Hodgkin/Non Hodgkin lymphoma(n)
17/25 12/14 P:0.364
Median age (range) 43(17-66) 42(20-66) P:0.622
Gender:F/M 26/16 18/8 P: 0.417
Pretransplantation status
CR/PR/Refractory(n)
29/5/8 19/2/5 P:0.623
Pretransplantation RT(n) 9 5 P:0.542Results: The groupswere comparable according to diagnosis,
age, gender, pretransplantation status of disease and pre-
transplantation radiotherapy. We also showed no difference
between the groups according to infused CD344 cells, the
number of febrile neutropenic days,hospitalization and
neutrophile,platelet engraftment kinetics (Table 2). Nausea/
vomitting was slightly higher in the BEAM group but the
rates of mucositis were similar between the groups.Table 2
Transplant outcomes
BEAM ICE
Mean of transplanted CD34+ cells 6.4 3.3 5.7 2.8 P:0.364
Day Number of febrile neutropenia 3(1-12) 4(1-10) P:0.613
Day number of hospitalization 26(9-50) 24(12-67) P:0.846
No of neutrophile engraftment day 12(9-34) 11(8-21) P:0.354
No of platelet engraftment day 12(9-25) 12(8-21) p:0.500Conclusion: BEAM is one of the earliest described and
traditionally accepted conditioning regimens in AHSCT of
Hodgkin/Non Hodgkin lymphoma patients. Attempts of
several groups to change the drugs in BEAM regimens
showed no evidence of more antitumor effect. We showed
comparable transplantation outcomes between ICE and
BEAM regimens.
We conclude that ICE regimen can be preffered as
a conditioning regimen instead of BEAM regimen in selected
patient groups.129
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Peripheral blood has largely replaced bone marrow as the
source of stem cells for autologous transplantation. The
number of cells infused is a key determinant of hematopoi-
etic recovery after transplantation. Peripheral blood stem cell
(PBSC) yield can be affected by several factors such as donor
characteristics, disease status and prior treatment regimens.
We retrospectively analyzed the effect of body mass index
(BMI) on PBSC mobilization in 164 patients with plasma cell
dyscrasias. Patients were segregated based on BMI <25(Group I), 25-30 (Group II) and>30 (Group III). Since G-CSF is
dosed according to the actual body weight, patients with
higher BMI received higher total G-CSF dose (as well as
higher dose per kg ideal body weight) but the median stem
cell yield per kg IBW was similar in the 3 groups. (I¼ 2.2 x
103 cells/Kg, II¼ 2.1 x 103 cells/Kg and III¼ 2.3 x 103 cells/Kg;
P ¼ .76). We also evaluated the effect of BMI on the mobi-
lizing efﬁcacy of plerixafor. In our institution, patients
receive G-CSF at a dose of 10 mg/Kg daily subcutaneous
injections for three consecutive days. Patients with periph-
eral CD34+ cell count less than 10 x 106/L are considered
“poor mobilizers” and plerixafor at a dose of 0.24 mg/Kg SQ
daily is initiated starting on the fourth day for a maximum of
four days or until target number of cells are collected. The
fold increase in the median peripheral blood CD34+ count
after one dose of plerixafor was 8.1 (7.1  57.2/uL), 6.8 (7.2 
49.5/uL) and 3.6 (11  40.3 /uL) in BMI groups I, II and III,
respectively (p¼0.0675). Similarly, the administration of
plerixafor in addition to G-CSF did not give as much beneﬁt
in stem cell yield in higher BMI groups as seen in BMI < 25
group (p¼0.0063 in BMI<25 group and P ¼ .30 in BMI >30).
The reasons for these effects are unclear. Homing of the HPCs
in the adipose tissue (AT) may be a factor in higher BMI
individuals as the adipose tissue has similar biochemical and
molecular microenvironment as the bone marrow. The
pathophysiologic changes associated with obesity may alter
the pharmacokinetics and pharmacodynamics of subcuta-
neously administered drugs leading to their impaired efﬁ-
cacy. We believe these initial observations may have
important implications for clinical practice. Prospective
studies are needed to validate these ﬁndings and explore
whether these effects can be mitigated by intravenous route
of plerixafor administration.130
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Prior to introduction of Plerixafor, CXCR4 receptor antago-
nist, up to 30% of patients in need of autologous stem cell
transplant were unable to collect adequate numbers of
peripheral blood stem cells (PBSCs). Plerixafor is currently
approved for hematopoetic stem cell mobilization and
collection in combination with Filgrastim in patients with
Non-Hodgkin Lymphoma (NHL) and multiple myeloma
(MM) undergoing autologous stem cell transplantation. Due
to high costs associated with use of Plerixafor, the above
combination is usually reserved for patients who are at high
risk of failure or fail previous stem cell mobilization.
We have administed Plerixafor to 13 patients that failed to
achieve adequate peripheral blood pre CD34 counts after
undergoing stem cell mobilization utilizing the combination
of chemotherapy and Pegﬁlgrastim. We retrospectively
reviewed our data to evaluate efﬁcacy and safety of the above
combination.
Thirteen patients (25-69 years) with lymphoma (NHL
n¼ 4 HL n¼ 2) and MM (n¼7) underwent treatment with ICE
based chemotherapy or Cytoxan 3 gm/m2 followed by
Abstracts / Biol Blood Marrow Transplant 19 (2013) S178eS193S180Neulasta 12 mg. Absolute pre CD34 count was performed on
peripheral blood upon recovery of neutrophils. If peripheral
blood CD34 count was below 10/microL, Plerixafor 0.24 mg/
kg/day with or without Neupogen 10mcg/kg/day was added.
Absolute pre CD34 values prior to Plerixafor ranged from
0e6. Pre CD34 values after Plerixafor ranged from 6 - 303.
Target CD34 yield per kg for NHL/HL patients was 2-5 X 106.
Target CD34 yield per kg for MM patients was 5-10 X 106.
Following this intervention 11 patients were able to
successfully complete stem cell mobilization and achieve
target yields. 2 MM patients did not meet the collection goal
for 2 transplants but did have sufﬁcient yield for one. Median
total CD34 yield per kg was 6.9 X 106. Mean total CD34 yield
for NHL/HL pts was 6.17 X 106 per kg. Mean total CD34 yield
for MMpts was 10.59 X 106 per kg. Mean total MNC yield was
14.23 X 108 per kg for NHL/HL pts. Mean total MNC yield was
8.71 X 108 per kg for MM pts. Average time for neutrophil
engraftment was 11.46 days. Average time for platelet
engraftment was 19.91 days. There were no major compli-
cations associated with the above combination and no
unanticipated side effects.
Combination of Plerixafor and Filgrastim can be safely and
successfully administered to patients with inadequate
peripheral blood pre-CD34 counts following chemotherapy
based mobilization regimens. This will prevent delay in the
transplantation process.131
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Background: Over 400 cases of pediatric severe aplastic
anemia (SAA) occur annually in the United States. A growing
number of children with SAA may have had their stem cells
harvested through cord blood collection. We describe a 9-
year-old male with SAA treated successfully with an autol-
ogous cord blood transplant following immunoablative
chemotherapy. With increasing numbers of cord blood
cryopreservations, the use of autologous cord blood in the
treatment of SAA might be considered as initial therapy.
Methods: A previously healthy 9-year-old Hispanic malewas
diagnosed with acquired SAA. Due to ongoing transfusion
support, and the lack of a sibling donor, anti-thymocyte
globulin and cyclosporine was initiated. Six months
following the start of immunosuppressive therapy, the
patient had no marrow recovery. An unrelated bone marrow
donor search revealed one 9 out of 10 matched unrelated
bonemarrow donor (HLA A antigenmismatch). One 10 out of
10 matched cord blood unit was available in the public cord
blood registry and further inquiry revealed that this donated
cord blood unit was an autologous unit. Given the lack of
response to immunosuppressive therapy, the risks associated
with the use of a mismatched unrelated donor hematopoi-
etic cell transplantation (HCT), and the availability of the
patients own cord blood unit, a decision was made to
proceed with autologous cord blood HCT.Results: The HCT preparative regimen included: ﬂudarabine
30 mg/m2/day from Day -6 to Day -4 for a total dose of 90
mg/m2. Cyclophosphamide 60 mg/kg/day was given from
Day -3 to Day -2 for a total dose of 120 mg/kg together with
MESNA prophylaxis. This was followed by a day of rest on
Day -1 and an infusion of 3.0 x 10e7 TNC/kg and 0.9 x 10e6
CD34+ /kg using an autologous cord blood unit on Day 0. His
absolute neutrophil count exceeded 500 cell/uL on Day + 21
and has subsequently remained above this threshold
without growth factor support. His platelet count was
greater than 20,000 /uL on Day + 36 with his last platelet and
packed red blood cell transfusion given on Day +20. The
patient was discharged at Day +27 and remains transfusion
independent at the time of his most recent clinical assess-
ment at Day +100. His Lansky performance status was 100 at
discharge and has remained so now at over 3 months
following transplant.
Conclusion: To our knowledge, this is the ﬁrst description of
a successful application of autologous cord blood HCT in
a pediatric patient with acquired SAA using an immunoa-
blative preparative regimen consisting of ﬂudarabine and
cyclophosphamide. We found autologous cord blood HCT
following an immunoablative combination of ﬂudarabine
and cyclophosphamide to be an effective and safe alternative
to the potential complications as well as morbidity and
mortality associated with the use of matched unrelated
donor HCT or the use of other alternative donor HCT
approaches.132
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Background: Engraftment syndrome (ES), characterized by
noninfectious fever, rash, diarrhea, and/or respiratory
symptoms during engraftment, can be associated with
increased morbidity and resource utilization (e.g., IV antibi-
otics, hospitalization) after autologous stem cell transplant
(ASCT). ES remains a clinical diagnosis, without conﬁrmed
biomarkers or standardized treatment recommendations.
Herein, we describe the clinical, laboratory, and outcomes
data from a large contemporary cohort of ASCT recipients
and suggest new diagnostic criteria.
Methods: 526 consecutive patients who underwent ASCT at
Mayo Clinic from 1/1/2009-12/31/2010 were included.
Diseases included: multiple myeloma, 48%; NHL, 30%;
amyloidosis, 12%; HL, 7%; and POEMS, 2%. Mayo Clinic criteria
for ES was deﬁned by a noninfectious fever of 38.3C from 4d
prior to WBC 500/ul up until ANC 500/ul and at least one of
the following: rash (erythematous with >25% trunk
involvement), diarrhea (>3 loose stools/d), or pulmonary
